Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Fuse›
Analysis
AddedJul 4, 2026
UpdatedJul 4, 2026
Fuse

Fuse

Pre-Seed

AI workflow automation for US healthcare providers covering insurance eligibility, claims, and revenue intelligence.

HQ
London, GB
Founded
2024
Accelerator
Y Combinator logoY CombinatorS24
Loading
Overview
Analysis
Compare
Fundraising
Employees
News

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths

Product Overview

Fuse's platform automates insurance verification, patient cost estimates, claims submission, and revenue intelligence for US healthcare providers. The system checks payer portals, places direct payer calls, and cross-references adjudicated claims to verify benefits at the CPT level.

It scrubs and submits claims, then consolidates eligibility, claims, and payment data into a financial dashboard for cash, denials, contract performance, and aged accounts receivable.

Market Outlook

US healthcare providers spend a significant share of revenue on financial administration, with eligibility errors and underpayments contributing to lost revenue. Recent advances in AI and machine learning make it feasible to automate payer portal checks, direct payer calls, and contract analysis at scale.

Regulatory pressure for price transparency, including CMS machine-readable files and the No Surprises Act, is creating demand for tools that turn complex payer data into actionable fee estimates and underpayment detection.

Competitive Advantages

Fuse combines payer portal checks, direct payer calls, and adjudicated claims data in a single model to verify benefits at the CPT code level, a granularity that generic eligibility tools often miss. It integrates into existing EMRs as a billing user without requiring new software or clearinghouse connections, which shortens onboarding to hours rather than months.

The platform learns payer-specific denial and approval patterns over time, applying them across pre-visit verification, pre-submission scrubbing, and post-denial retry.